PAVmed Inc. (PAVM) revealed Third Quarter 2020 Financial Results and Business Update
The Company and its subsidiaries Lucid Diagnostics and Solys Diagnostics received a Business Update from PAVmed Inc. (Nasdaq: PAVM) and addressed the details of financial operations for 3 and 9 months ended 30 September 2020. Research and development expenditures for 3 months ended 30 September 2020 amounted to $2.6 million, with general and administrative costs […]